Intellia Therapeutics (NTLA) Presents Additional Lonvo-z Data; BLA Review Target Is March 10, 2027
Intellia Therapeutics (NTLA) presented additional data for lonvo-z, showing an 81% decrease in monthly attack rates in HAELO Phase 3 trial. All patients on 50 mg were LTP-free. The FDA accepted its BLA in September 2026 with a Priority Review and a PDUFA target date of March 10, 2027. Intellia is hosting an investor webcast today.
How this was made
The 30-second read
Why it matters
The regulatory milestone and efficacy data together create a catalyst that could drive the stock higher ahead of the PDUFA decision.
Market read
First‑time disclosure of a BLA acceptance and priority review for a late‑stage rare‑disease therapy, likely to move NTLA shares.
What to watch
Potential competition from other HAE therapies and the need for reimbursement approvals could moderate long‑term upside.
Background
Intellia Therapeutics announced additional clinical data for its lonvo‑z candidate at ACAAI 2026 and disclosed FDA BLA acceptance with priority review.
Ticker impact
Intellia Therapeutics received FDA acceptance of its BLA for lonvo‑z and priority review, with new Phase 3 data showing an 81% attack‑rate reduction in hereditary angioedema patients.
likely upward pressure as investors price in the chance of approval by the March 10, 2027 PDUFA target date
First disclosure of BLA acceptance and priority review for a late‑stage biotech typically drives share price higher, especially with compelling efficacy data.
Market effects
Strengthens the biotech/rare‑disease therapeutic sector by highlighting a potential new approved treatment for hereditary angioedema.
Positive for US biotech stocks and may boost related ADRs and biotech ETFs.
Adds to global pipeline confidence for gene‑editing therapies, potentially influencing investor sentiment in international biotech markets.
Counterpoint
If the FDA later raises concerns about safety or manufacturing, the current upside could reverse sharply.
Key entities
- companyIntellia Therapeutics
US‑listed biotech developing gene‑editing therapies.
- regulatorFDA
U.S. Food and Drug Administration, granted BLA acceptance and priority review.
